Q-linea AB
16.00
SEK
+0.20
(+1.27%)
Q-linea AB
STO:QLINEA
(Nasdaq Stockholm)
Recent
price
16.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.- Similar Companies
- Business
- Q-linea AB (publ) is a Sweden-based medical technology company specializing in the development and manufacturing of in-vitro diagnostic (IVD) solutions for infectious diseases. Its core product, ASTar, is a fully automated instrument for rapid antibiotic susceptibility testing (AST), designed to determine bacteria's antimicrobial susceptibility directly from positive blood cultures within three to six hours, significantly accelerating the diagnosis and treatment of sepsis in hospital patients. The company offers disposables including the ASTar BC G- consumable kits, which complement its diagnostic instruments. Q-linea's product portfolio is aimed at hospital laboratories and addresses key medical needs related to sepsis diagnosis and antibiotic resistance management. The company operates primarily in Europe and North America, with headquarters in Uppsala, Sweden, and regional offices in Italy and the USA. In the last 1-2 years, Q-linea has undergone several significant operational and strategic developments. In 2024, the company achieved FDA 510(k) clearance for ASTar, facilitating its launch in the U.S. market. Recently, Q-linea submitted an FDA expansion application for ASTar BC G- panel to broaden its microbial and antimicrobial claims, aimed at enhancing the product's diagnostic coverage. The company is actively expanding its geographic reach through distributor partnerships, including new clinical evaluations and contracts in the Gulf Cooperation Council region and France. It also completed a capital raise including a SEK 225 million rights issue in late 2024 to support commercial expansion and product development. Q-linea's updated commercialization strategy focuses on key European markets including the UK, Italy, and Benelux, while building its commercial organization in the USA and Italy. These initiatives underpin the company's goal to contract and place 30 to 40 ASTar units by the end of 2025. Founded in 2008, Q-linea operates within healthcare services and medical diagnostic technology segments, targeting hospital laboratories and healthcare providers for infectious disease testing. The company's innovations emphasize rapid diagnostics to reduce antibiotic misuse and improve patient outcomes globally. Q-linea remains committed to enhancing its ASTar system with expanding test panels beyond blood culture applications and increasing its geographic availability through strategic alliances and direct market efforts. Q-linea AB is publicly traded on the Nasdaq Stockholm exchange under the ticker QLINEA.ST. The company continues to develop its infectious disease diagnostic tools with a strong focus on automation, speed, and clinical impact seeking to contribute to sustainable healthcare solutions worldwide.